BLOOMINGTON, INDIANA-April 17, 2009-BioConvergence, a Bloomington, Indianabased contract solutions provider to the biotech and pharmaceutical industries, celebrates its 3rd year of operations in the life sciences industry. Recent accomplishments include:
-Retaining 99% of its more than 100 clients, including 10% from the State of Indiana and 10% from outside the United States
-Attracting more than 40 life sciences professionals and expanding facilities to serve more clients
-Adding new clinical manufacturing, packaging and QC testing services to complement its existing core of product development and supply chain
management services
-Consistently increasing revenue by providing the functions that enable clients to reach the clinic faster at reduced costs
-Leveraging the strengths of clients, employees and board members to become a collaborative partner for companies adopting the Fully Integrated Pharmaceutical Network, or FIPnet, drug development model
“We are blessed to be celebrating this special day,” said Alisa Wright, CEO and founder of BioConvergence. “At a time when challenging economic conditions have changed the game for virtually all businesses and industries, we are grateful our clients continue to trust us to develop their life-saving products.”
About BioConvergence LLC
BioConvergence is a leading contract solutions provider for the biotech and pharmaceutical industries. We offer the following services for our global client base: product development, cGMP supply chain & materials management, toxicology and clinical materials manufacturing & packaging, QC testing and consulting services. BioConvergence is the first solutions provider to offer its secure E-Transparency Solution enabling clients to access their data 24/7. BioConvergence is a women-owned, small business based in Bloomington, Indiana. For more information, visit us at www.bioc.us.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.